Our Approach

Focus on key drivers of ageing.

There are currently over 720 million persons over the age of 65 globally which is expected to double by 2050 to >1.5 billion.¹  Diseases of ageing, including loss of mobility, metabolic dysfunction, and cognitive impairment increase with age and contribute dramatically to loss of healthspan and healthcare costs.

As we age we lose memory, strength and metabolic fitness. We can prevent these symptoms of ageing through discovery and development of preventative therapies. We pioneer deep learning to expand our understanding of fundamental ageing processes.

Brain

11-20% of people over 65 experience subjective cognitive decline resulting in >$300B in healthcare costs per year in the US alone. However some people can improve their symptoms with lifestyle modification, which indicates potential for new preventative therapies.²

brain illustration

Liver

The liver is a major driver of regulating the body’s metabolism, ensuring homeostatic energy balance and regulating immune and even brain activity.  Approximately 1 in 4 adults globally have fatty liver disease (NAFLD) with increasing prevalence with age.  While ageing reduces the liver’s regenerative capacity, this can be resolved through lifestyle choices.³

Liver illustration

Muscle

Muscle strength decreases on average of 10% per decade after age 40. Loss of or reduced mobility with age contributes to nearly 3 million fall injuries among the elderly in the US alone, contributing to nearly $50B in healthcare costs.  Loss of muscle, or sarcopenia, can be delayed or reversed by exercise.

Muscle illustration

Changing the trajectory of health
to achieve rejuvenation.

Develop

Clarity from Complexity

Complex biologic data necessitates powerful computational approaches to unlock information. Our Resonance platform collects and synthesizes optimal training data to produce advanced deep learning models which autonomously drive better decisions at large scale.

In Collaboration with
Roche Logo
Resonance
0.914
Expert
0.868
Average
0.803
Novice
0.759

Transforming data interpretation

Arrive technology unravels complexity. Our Resonance platform increases the confidence for breast cancer diagnosis, directs precision medicine, and enables clinical trial enrollment.

Validate

Arrive’s in vitro platform

Arrive’s platform combines aging cell biology, drug screening and machine learning to discover novel targets, safe and effective molecules, and advance our portfolio through clinical testing to create patient impact.

Impact

Translate biology into healthspan

We advance near-term indications of age-related diseases. In so doing, we build a sustainable and proprietary advantage for the long-term. In parallel, we advocate for change in healthcare to make a system that can better support our innovations in preventing and treating age-related diseases.

Connect

Partnering

Arrive evaluates in-licensing opportunities from discovery through clinical stage assets. Please contact us with non-confidential partnership proposals or inquiries about opportunities.

Contact Partnering

Support our Science

Arrive’s mission is to develop therapies that improve healthspan for all people. We are supported by  individuals and organisations that share this aspiration and welcome you to join us on this mission. 

Contact Science

Careers

We invite inquiries from exceptional drug development, biology and engineering talent. Please send resume and cover letter.

Contact Careers